Professor Mark Kearney

Profile

I am a British Heart Foundation Professor of Cardiovascular and Diabetes Research and clinical cardiologist with an interest in the mechanisms underlying diabetes related heart disease and the natural history and new treatments for patients with heart failure. My research group includes members with a wide range of skills addressing the link between diabetes and cardiovascular disease. Within ten years over 500million people will suffer from type 2 diabetes which we now know is a disease of the large and small blood vessels.

My team are working on the link between changes in insulin and IGF-1 signalling in the blood vessel wall and diabetes with the aim of designing new ways of treating the devastating cardiovascular complications of type 2 diabetes. I am currently on the research committee of Diabetes UK having served on the project and fellowship committees of the British Heart Foundation. I am passionate about training tomorrow’s leaders in cardiovascular research.

Responsibilities

• BHF Professor of Cardiovascular and Diabetes Research
• Consultant Cardiologist

Research interests

Our laboratory is exploring the mechanistic link between endothelial function and insulin resistance.

British Heart Foundation Chair Award

BHF Chair of Cardiovascular and Diabetes Research.

£2,277,754 over 10 years

2018–2028

National Institute for Health & Care Research Senior Investigator Award

Senior Investigator

£80,000

2025-2029

Project grants

British Heart Foundation

A novel signalling loop pivotal to type 2 diabetes induced tissue damage

£895357 over 4 years

2023 to 2027

Novel role for endothelial cell insulin like growth factor-1 receptor in regulating

£337215.25 over 3 years

2024 to 2027

Manipulating insulin like growth factor-1 receptor expression as a therapeutic strategy to control insulin sensitivity and tissue repair.

£1376166 over 5 years.

2015–2020

Dissecting the role of endothelial insulin-like growth factor-1 signalling in the vascular and metabolic complications of obesity-induced type 2 diabetes mellitus.

£299121 over 3 years.

2019-2022

Astra Zeneca

Reducing Hospitalisation in Patients with Heart Failure

£175967 over 3 years

2022-2025

Qualifications

• MBChB
• FRCP
• DM

Professional memberships

• British Atherosclerosis Society

Student education

Dean of the School of Medicine

Research groups and institutes

• Discovery and Translational Science
• British Heart Foundation - Cardiovascular research
• Multidisciplinary Cardiovascular Research Centre